HUMANWELL HEALTHCARE sees an upgrade to Slightly Positive due to a better fundamental star rating
The general evaluation of HUMANWELL HEALTHCARE (CN), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date December 28, 2021, the closing price was CNY 22.07 and its potential was estimated at CNY 25.58.Wuhan Humanwell Hi-Tech Industry is engaged in the research, development, production, provision of technical and consultation services and sale of medicine, medical equipment, chemical, biological engineering, electronic, telecommunication, new materials and optical, mechanical and electronic integration; the wholesale and retail of hardware, medical appliances, computers and its parts, automobile spare-parts, telecommunication equipment, and electromechanical; the development of real estate; the sale of commercial buildings; and the export of self-produced products.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.